Drag a card by its title · ⚙ to size, swap or remove

The company

Data I/O Corporation

DAIO · Nasdaq

Health CareLife-science toolsNot moving yet

DAIO stood above a rising 150-day average in 16 of the last 52 weekly readings, and has been out of that trend for the last 12 weeks. It is 14.9% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 12
Industry in uptrend: 52% +4 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 33 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 16 of 52 weeks.

17 Apr – 16 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months0

Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders33+6 on the quarter

New · exited8 · 2

Reported value$11.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
Kanen Wealth Management LLCunchanged · filed 13 Aug 2026	839,421$3.3M	00.0%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026	392,443$1.5M	-15,200−3.7%
Penbrook Management LLCreduced · filed 23 Jul 2026	355,850$1.4M	-1,000−0.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	323,672$1.3M	+24,275+8.1%
Kovack Advisors, Inc.added · filed 29 Jul 2026	285,481$1.1M	+17,500+6.5%
DIMENSIONAL FUND ADVISORS LPunchanged · filed 11 Aug 2026	140,679$554K	00.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	115,057$453K	+28,190+32.5%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026	86,869$342K	+86,869
ESSEX INVESTMENT MANAGEMENT CO LLCreduced · filed 6 Aug 2026	74,558$294K	-83−0.1%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026	58,643$231K	+12,790+27.9%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Charles Joseph DiBona Vice President & CFO · last 1 Sep 20260 · 0

Edward J. Smith Director · last 8 Jul 20261 · 0

Garrett Riley Larson Director · last 8 Jul 20260 · 0

Sally A. Washlow Director · last 8 Jul 20260 · 0

Steven M. Waszak Director · last 8 Jul 20260 · 0

William O. Wentworth President · last 3 Dec 20252 · 0

Douglas Wells Brown Director · last 15 May 20253 · 5

Gerald Yat Ng Vice President CFO · last 3 Jul 20240 · 0

Anthony Ambrose President · last 1 Jun 20243 · 11

Michael R. Tidwell VP Mktg & Corp Bus Dev · last 1 Jun 20240 · 0

Rajeev Gulati Vice President CTO · last 1 Jun 20240 · 10

Joel S. Hatlen Vice President CFO COO · last 1 Jun 20230 · 12

Same industry

OABI OmniAbLeading+65%

TXG 10x GenomicsLeading+60%

AVTR AvantorLeading+47%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+37%

CRL Charles River Laboratories InternationalLeading+35%

MASS 908 DevicesLeading+31%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202549.3%

Operating profit marginFY 2025 · to 31 Dec 2025-23.8%

Free cash flow marginFY 2025 · to 31 Dec 2025-13.0%

Return on capital employedFY 2025 · to 31 Dec 2025-33.7%

Research spendFY 2025 · to 31 Dec 202530.4%

Share count trendFY 2025 · to 14 Apr 20260.0%

Cash and equivalentsFY 2025 · to 31 Dec 2025$7.9M

Free cash flowFY 2025 · to 31 Dec 2025−$2.8M

Analyst forecasts

No analyst forecasts yet.